Today the company announced it will discontinue a trial studying its experimental therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-10-16 08:48:202023-10-16 08:56:53Omeros terminates kidney disease trial as therapy fails in late-stage study
